Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...
When the FDA awarded Biohaven Pharmaceuticals’ migraine med Nurtec ODT with a second indication last month, the company paraded the drug as the only option to both prevent and treat migraines. Now, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results